Valmet Reports Strong Q3 2026 Orders and Higher Comparable EBITA

Valmet reported 25% organic growth in Q3 2026 order intake and comparable EBITA of €169 million. It reaffirmed 2026 guidance for sales to remain flat versus 2025 and EBITA to be flat or higher than 2025’s €620 million. A strategic review of a potential separation of two business units is ongoing, with about €10 million in related costs expected in Q4. Strong biomaterials capital orders, particularly in China and APAC, are expected to expand Valmet’s installed base and future service revenue.